keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/29125261/hepatitis-b-and-liver-transplantation
#1
Alberto Ferrarese, Alberto Zanetto, Francesco P Russo
Liver transplantation (LT) is the only effective treatment for hepatitis B-virus (HBV) related end stage liver disease, even if the outcome of these patients, has significantly improved after introduction of effective and well tolerated nucleos/tide analogues (NUC). Pre-transplant therapy has been initially based on lamivudine, but entecavir and tenofovir represent the currently recommended first-line therapeutic option in patients with HBV decompensated cirrhosis. After LT, the development of hepatitis B immunoglobulin (HBIG) in the early 1990s change dramatically the prognosis of these patients by reducing the incidence of HBV recurrence and increasing survival rate...
November 10, 2017: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/29119705/on-treatment-changes-of-liver-stiffness-at-week-26-could-predict-2-year-clinical-outcomes-in-hbv-related-compensated-cirrhosis
#2
Shanshan Wu, Yuanyuan Kong, Hongxin Piao, Wei Jiang, Wen Xie, Yongpeng Chen, Lungen Lu, Anlin Ma, Shibin Xie, Huiguo Ding, Jia Shang, Xuqing Zhang, Bo Feng, Tao Han, Xiaoyuan Xu, Lijuan Huo, Jilin Cheng, Hai Li, Xiaoning Wu, Jialing Zhou, Yameng Sun, Xiaojuan Ou, Hui Zhang, Hong You, Jidong Jia
BACKGROUND & AIMS: It is unclear whether liver stiffness measurement (LSM) dynamic changes after anti-HBV treatment could predict the risk of liver related events (LREs), particularly in patients with HBV-related compensated cirrhosis. METHODS: Treatment-naïve patients with HBV-related compensated cirrhosis were enrolled. All patients were under entecavir-based anti-viral therapy, and followed up every 26 weeks for two years. The association between LSM and LREs were analyzed by Cox proportional hazard model and Harrell C-index analysis...
November 8, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29116050/real-world-evidence-for-nucleoside-nucleotide-analogues-in-a-5-year-multicentre-study-of-antiviral-naive-chronic-hepatitis-b-patients-in-china-52-week-results
#3
Jidong Jia, Hong Tang, Qin Ning, Jiaji Jiang, Xiaoguang Dou, Mingxiang Zhang, Shuqin Zhang, Jia Shang, Wei Lu, Yinong Ye, Xin Wang, Mingshu Li, Jie Liu, Qingyan Bo, Wenzhong Tan
BACKGROUND: In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of various nucleos(t)ide analogue (NUC) regimens in treatment-naïve patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal observational study therefore investigated the real-world clinical management and efficacy of NUC therapy in treatment-naïve CHB patients in China. METHODS: Treatment-naïve CHB patients initiated on NUC therapy were enrolled from 63 hospitals in tier-2 Chinese cities...
November 8, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/29108198/-clinical-effect-of-entecavir-versus-tenofovir-in-treatment-of-hbeag-positive-chronic-hepatitis-b-patients-with-a-high-viral-load-a-comparative-analysis
#4
H Shi, X Y Li, J Y Zhu, C S Lin, Y Zhang
Objective: To investigate the clinical effect and safety of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in the treatment of previously untreated HBeAg-positive chronic hepatitis B (CHB) patients with a high viral load. Methods: A retrospective analysis was performed for the clinical data of 152 HBeAg-positive CHB patients with a high viral load (HBV DNA≥10(6) IU/ml) who were firstly treated with ETV (ETV group) or TDF (TDF group), with 76 patients in each group. The serum levels of alanine aminotransferase (ALT), HBV DNA, HBeAg, anti-HBe, creatinine, and creatine kinase were measured at baseline, and the patients were followed up and evaluated at weeks 4, 12, 24, 36, 48, 60, 72, 84, and 96 of treatment...
October 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29095799/comparing-efficacy-of-lamivudine-adefovir-dipivoxil-telbivudine-and-entecavir-in-treating-nucleoside-analogues-na%C3%A3-ve-for-hbeag-negative-hepatitis-b-with-medium-hepatitis-b-virus-hbv-dna-levels
#5
Hong Shi, Zongping Han, Jian Liu, Jinfang Xue, Shuya Zhang, Zhe Zhu, Jinyu Xia, Mingxing Huang
BACKGROUND The antiviral effect of HBV in different nucleos (t) ide analogues is still not well known. This study was conducted to compare the effectiveness of lamivudine (LMV), adefovir dipivoxil (ADV), telbivudine (LdT), and entecavir (ETV) monotherapy in chronic HBeAg-negative hepatitis B patients with medium load of HBV DNA. MATERIAL AND METHODS The effective data of 207 patients treated by LMV (n=43), ADV (n=57), LdT (n=54) or ETV (n=53) were collected and analyzed during 144-week follow-up by retrospective analysis...
November 2, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29095312/hepatitis-b-virus-infection-in-an-hbsab-positive-lymphoma-patient-who-received-chemotherapy-a-case-report
#6
Fu-Biao Kang, Ling Wang, Dian-Xing Sun
RATIONALE: Tumor chemotherapy could weaken the immune system of patients, which might enhance the body sensitivities to the exogenous pathogens, among which the hepatitis B virus (HBV) infection should be concerned because of the higher chances of infection and the severe outcomes, especially in East Asia. The titer level of hepatitis B surface antibody (HBsAb) higher than 10 IU/L is considered to offer immunocompetent individuals adequate protection. However, whether this level is enough to the tumor patients during chemotherapy remains unclear...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29093232/treatment-response-monitoring-of-chronic-hepatitis-b-patients-using-transient-elastography-and-aspartate-aminotransferase-to-platelet-ratio-index-apri
#7
Ignatius R Tenggara, C Rinaldi Lesmana, Rino A Gani
BACKGROUND: Hepatitis B is endemic in Indonesia and treatment response need to be monitored during and after antiviral therapy. Liver stiffness measurement and alanine aminotransferase-to-platelet ratio index (APRI) are noninvasive method to detect liver fibrosis available in Indonesia. However, little is known about their ability to evaluate treatment response in chronic hepatitis B (CHB) patients in Indonesia. This study aimed to investigate liver stiffness changes by transient elastography (TE) and APRI before and after one-year oral antiviral treatment in CHB patients and the correlation between TE and APRI...
July 2017: Acta Medica Indonesiana
https://www.readbyqxmd.com/read/29089265/tenofovir-entecavir-and-lamivudine-in-patients-with-severe-acute-exacerbation-and-hepatic-decompensation-of-chronic-hepatitis-b
#8
Jung Gil Park, Yu Rim Lee, Soo Young Park, Heon Ju Lee, Won Young Tak, Young Oh Kweon, Se Young Jang, Jae Min Chun, Young Seok Han, Keun Hur, Hye Won Lee, Min Kyu Kang
OBJECTIVE: To compare the efficacy of and mortality after lamivudine (LAM), tenofovir (TDF), and entecavir (ETV) treatment in patients with severe acute chronic hepatitis B (CHB) exacerbation. METHODS: We analyzed 91 patients with severe acute CHB exacerbation treated with LAM (n=28), TDF (n=26), or ETV (n=37) for 10 years. The primary endpoint was overall mortality or liver transplantation (LT) by 48 weeks. The determined predictors of mortality, virologic and biochemical responses, and drug resistance were also evaluated...
October 28, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29082652/long-term-outcome-of-telbivudine-versus-entecavir-in-treating-higher-viral-load-chronic-hepatitis-b-patients-without-cirrhosis
#9
H-Y Pan, H-Y Pan, W-Y Song, W Zheng, Y-X Tong, D-H Yang, Y-N Dai, M-J Chen, M-S Wang, Y-C Huang, J-J Zhang, H-J Huang
Chronic hepatitis B (CHB) patients with higher hepatitis B virus (HBV) load (higher viral load [HVL], HBV DNA ≥1 × 10(7) copies/mL) require antiviral therapy, but data for evaluating the long-term outcome of this therapy with antiviral agents remain limited. We comparatively evaluated the efficacy and the safety of nucleoside analogues in 179 noncirrhotic CHB patients with HVL over 5 years. The HBeAg-positive (n = 104) or HBeAg-negative (n = 75) patients were treated consecutively with telbivudine (LdT, n = 88) or entecavir (ETV, n = 91) and evaluated for viral response, drug resistance and safety...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082651/comparison-of-208-week-sequential-therapy-with-telbivudine-and-entecavir-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-responses-to-24%C3%A2-weeks-of-peg-ifn%C3%AE-2a-therapy-an-open-labelled-randomized-controlled-real-life-trial
#10
X D Luo, X F Chen, Y Zhou, X P Chen
The purpose of the study was to compare the efficacy and safety of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy. This was an open-label, randomized, controlled, "real-life" trial. HBeAg-positive CHB patients with serum HBV DNA ≥5.0 lg IU/mL and a < 1 lg IU/mL decline of HBsAg level from baseline who underwent at least 24 weeks of Peg-IFNα-2a therapy were included. Enrolled patients were randomized to receive either telbivudine (600 mg/d, n = 95) or entecavir (0...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082649/peginterferon-is-preferable-to-entecavir-for-prevention-of-unfavourable-events-in-patients-with-hbeag-positive-chronic-hepatitis-b-a-five-year-observational-cohort-study
#11
S-Y Li, H Li, Y-L Xiong, F Liu, M-L Peng, D-Z Zhang, H Ren, P Hu
At present, the long-term effects of pegylated interferon-α (PEG-IFN-α) and entecavir (ETV) are controversial. Studies directly compared the long-term outcomes of these two drugs have not been completed. This study was designed to compare the clinical outcomes of PEG-IFN-α vs ETV therapy in Chinese patients with chronic HBV infection. From September 2008 to December 2016, a large, observational, open-label, prospective cohort study of HBeAg-positive patients with CHB who received PEG-IFN-α or ETV therapy was carried out at the Second Affiliated Hospital of Chongqing Medical University...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29082645/efficacy-and-safety-of-three-adefovir-based-combination-therapies-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-response-to-adefovir-monotherapy
#12
M-L Wang, E-Q Chen, D-M Zhang, L-Y Du, L-B Yan, T-Y Zhou, X-Z Lei, B-J Lei, J-J Lu, J Liao, H Tang
Although high potent nucleos(t)ide analogues are strongly recommended as first-line therapy for chronic hepatitis B (CHB) in China, some patients are still being treated with adefovir disoproxil (ADV), especially those low-income patients whose health insurance could not reimburse the drug cost. Therefore, the management of patients who have failed ADV therapy or who sustained renal damage during ADV therapy remains an important clinical problem in China. This retrospective study aimed to compare the efficacy and safety of lamivudine (LAM), telbivudine (LdT) or entecavir (ETV) add-on strategies to optimize the treatment of patients with prior suboptimal response to ADV monotherapy...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29081251/an-update-on-the-treatment-options-for-hbv-hcv-coinfection
#13
Evangelista Sagnelli, Caterina Sagnelli, Margherita Macera, Mariantonietta Pisaturo, Nicola Coppola
Despite the reciprocal inhibition exerted by HBV and HCV genomes, dual HBV/HCV infection is associated with more severe forms of liver disease and warrant effective treatment. Areas covered: A careful evaluation of disease progression to establish the predominance of one virus over another, concomitant HIV infection and comorbidities is essential to make the best therapy choices. In most virological conditions interferon (IFN)-based treatment has been replaced by a combination of different classes of second generation directly acting antivirals (DAAs), which offer better tolerability and HCV eradication in 95% of cases...
November 2, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29079518/efficacy-of-nvr-3-778-alone-and-in-combination-with-pegylated-interferon-vs-entecavir-in-upa-scid-mice-with-humanized-livers-and-hbv-infection
#14
Klaus Klumpp, Takashi Shimada, Lena Allweiss, Tassilo Volz, Marc Lütgehetmann, G Hartman, Osvaldo A Flores, Angela M Lam, Maura Dandri
BACKGROUND & AIMS: NVR3-778 is a capsid assembly modulator in clinical development. We determined the in vivo anti-viral efficacy and effects on innate and endoplasmic reticulum (ER) stress responses of NVR3-778 alone or in combination with pegylated interferon alpha (peg-IFN) and compared with entecavir. METHODS: We performed 2 studies, with a total of 61 uPA/SCID mice with humanized livers. Mice were infected with a HBV genotype C preparation; we waited 8 weeks for persistent infection of the human hepatocytes in livers of mice...
October 24, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29079285/a-novel-orally-available-small-molecule-that-inhibits-hepatitis-b-virus-expression
#15
Henrik Mueller, Steffen Wildum, Souphalone Luangsay, Johanna Walther, Anais Lopez, Philipp Tropberger, Giorgio Ottaviani, Wenzhe Lu, Neil John Parrott, Jitao David Zhang, Roland Schmucki, Tomas Racek, Jean-Christophe Hoflack, Erich Kueng, Floriane Point, Xue Zhou, Guido Steiner, Marc Lütgehetmann, Gianna Rapp, Tassilo Volz, Maura Dandri, Song Yang, John A T Young, Hassan Javanbakht
BACKGROUND & AIMS: The hallmarks of chronic HBV infection are a high viral load (HBV DNA) and even higher levels (>100-fold in excess of virions) of non-infectious membranous particles containing the tolerogenic viral S antigen (HBsAg). Currently, standard treatment effectively reduces viremia but only rarely results in a functional cure (defined as sustained HBsAg loss). There is an urgent need to identify novel therapies that reduce HBsAg levels and restore virus-specific immune responsiveness in patients...
October 24, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29077211/switching-from-tenofovir-and-nucleoside-analogue-therapy-to-tenofovir-monotherapy-in-virologically-suppressed-chronic-hepatitis-b-patients-with-antiviral-resistance
#16
Dong Yun Kim, Hye Won Lee, Jeong Eun Song, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
It is unclear whether chronic hepatitis B (CHB) patients with antiviral resistance, who achieve a complete virologic response (CVR) with tenofovir disoproxil fumarate (TDF) and nucleoside analogue (NUC) combination therapy, maintain CVR if switched to TDF monotherapy. We investigated the persistence of CVR after cessation of NUC in virologically suppressed antiviral resistant CHB patients using TDF+NUC combination therapy. This study recruited 76 antiviral-resistant CHB patients showing CVR on TDF+entecavir (ETV) (n = 52), TDF+lamivudine (LAM; n = 14), and TDF+telbivudine (LdT; n = 10) combination therapy, who were switched to TDF monotherapy as step-down therapy...
October 27, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/29072673/seven-year-treatment-outcome-of-entecavir-in-a-real-world-cohort-effects-on-clinical-parameters-hbsag-and-hbcrag-levels
#17
Yuk-Fai Lam, Wai-Kay Seto, Danny Wong, Ka-Shing Cheung, James Fung, Lung-Yi Mak, John Yuen, Chun-Kong Chong, Ching-Lung Lai, Man-Fung Yuen
OBJECTIVES: We aimed to determine the levels of alanine aminotransferase (ALT), hepatitis B virus DNA (HBV DNA), HBsAg, and a novel viral marker (hepatitis B core-related antigen (HBcrAg)); hepatitis B e antigen (HBeAg) seroconversion and drug resistance rates after 7 years of entecavir treatment in chronic hepatitis B (CHB) patients. METHODS: Two hundred and twenty-two Chinese CHB patients on continuous entecavir treatment were recruited. Serologic, virologic, biochemical outcomes, and the occurrence of entecavir signature mutations were determined...
October 26, 2017: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/29066092/longitudinal-monitoring-of-liver-stiffness-by-acoustic-radiation-force-impulse-imaging-in-patients-with-chronic-hepatitis%C3%A2-b-receiving-entecavir
#18
Sheng-Di Wu, Hong Ding, Li-Li Liu, Yuan Zhuang, Yun Liu, Li-Sha Cheng, Si-Qi Wang, Yu-Jen Tseng, Ji-Yao Wang, Wei Jiang
BACKGROUND: Acoustic radiation force impulse (ARFI) imaging measures liver stiffness (LS), which significantly correlates with the stage of liver fibrosis in treatment-naive patients with chronic hepatitis B (CHB). AIM: We aimed to prospectively assess the clinical usefulness of ARFI during long-term antiviral therapy in CHB. METHOD: Seventy-one CHB patients were consecutively recruited and paired liver biopsies were performed in 27 patients...
October 21, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/29056011/-study-on-the-correlation-of-the-effect-of-entecavir-on-th1-th2-cytokines-level-in-the-treatment-of-chronic-hepatitis
#19
L Li, Y B Jing, J Liu, C L Wang, B Liu
Objective: To explore the expression level of peripheral blood Th1/Th2 type cytokines of chronic hepatitis b (CHB) patients in the entecavir (ETV) antiviral treatment, analyze the relationship between various cytokines, and the correlation among of cytokines and HBV DNA loads. Methods: Luminex Liquid Chip Technology was applied to detect the peripheral blood Th1/Th2 type cytokines expression level of CHB patients; At the same time, liver function was detected by Fully Automatic Biochemical Analyzer; HBV DNA loads were detected by PCR Method; Hepatitis b virology markers were detected by Chemiluminescence Method...
August 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29056009/-clinical-effect-and-safety-of-144-week-treatment-with-entecavir-capsules-in-treatment-na%C3%A3-ve-hbeag-positive-patients-with-chronic-hepatitis-b
#20
D C Cai, C Pan, W H Yu, S S Dang, J Li, S M Wu, N Jiang, M R Wang, Z H Zhang, F Lin, S J Xin, Y F Yang, B S Shen, H Ren
Objective: To investigate the clinical effect and safety of entecavir capsules in the treatment of treatment-naïve HBeAg-positive patients with chronic hepatitis B (CHB). Methods: A total of 158 HBeAg-positive CHB patients were given oral entecavir capsules at a dose of 0.5 mg/time once a day for 144 weeks. Clinical outcome and safety were evaluated at baseline and at 24, 48, 72, 96, 120, and 144 weeks of treatment respectively. The Fisher's exact test was used for the analysis of categorical data. Results: After 144 weeks of treatment, 90...
August 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"